NCT01715272已完成1 期
A Clinical Investigation to Demonstrate the Performance of a New Enema (TF037) in Distal Bowel Cleansing Compared With Fleet Enema
Norgine1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2012年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Performance of TF037 in distal bowel cleansing compared to Fleet enema using the Harefield Cleansing scale
研究概览
简要总结
This study is designed to assess the difference between the performance of a new enema (TF037) against Fleet enema in distal bowel cleansing.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Care Provider)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male or female subjects [as determined by medical history, physical examination, laboratory test values, vital signs and 12-lead electrocardiograms (ECGs) at screening] aged 18 to 60 years.
- •Non-smokers from 3 months before enema administration and for the duration of the clinical investigation.
- •Body mass index (BMI) ≥ 18 and ≤ 35 kg/m
- •Must voluntarily provide written informed consent to participate in the clinical investigation.
- •Must understand the purposes and risks of the clinical investigation and agree to follow the restrictions and schedule of procedures as defined in the clinical investigation plan, and as confirmed during the informed consent process.
- •Female subjects must be postmenopausal (for at least one year and confirmed by a serum follicle stimulating hormone (FSH) test at screening), surgically sterile, practising true sexual abstinence or must use an effective method of contraception.
- •Female subjects of child-bearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test at check-in of each period.
- •The subject's primary care physician must confirm that there is nothing in their medical history that would preclude their enrolment into this clinical investigation.
- •Must be willing to consent to have data entered into The Over Volunteering Prevention System (TOPS).
排除标准
- •Subjects with a history or presence of significant cardiovascular disease, pulmonary, hepatic, gallbladder or biliary tract, renal, haematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic or psychiatric disease.
- •Subjects with a history or presence of organic or functional gastrointestinal conditions (e.g. chronic constipation, irritable bowel syndrome, inflammatory bowel disease).
- •Subjects with a clinically relevant history or presence of abnormal gastrointestinal motility.
- •Subjects with a significant history of hereditary bowel disorders.
- •Subjects with abnormal findings on the digital rectal examination performed at screening.
- •Use of laxatives or motility altering drugs in the 3 months preceding enema administration.
- •Use of any prescription or over-the-counter medication (including vitamins, herbal and mineral supplements) within 14 days prior to enema administration (or within 5 half lives if longer), with the exception of Investigator-approved hormonal contraceptives, hormone replacement therapy (HRT) and occasional paracetamol, aspirin or ibuprofen.
- •Participation in a clinical drug study during the 30 days preceding enema administration in this clinical investigation.
- •Donation of blood or blood products within 30 days prior to enema administration or during the clinical investigation, except as required for this clinical investigation
- •Pregnant or lactating females.
- •Any clinically significant illness within 28 days prior to enema administration.
- •History or presence of any significant drug allergy, or a known allergy or contraindication to trisodium citrate, Fleet® enema or midazolam.
- •Laboratory values at screening which are deemed to be clinically significant, unless agreed in advance by the Sponsor's Medical Representative and Principal Investigator.
- •Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
- •Current or history of drug or alcohol abuse within the 12 months prior to enema administration, or a positive drugs of abuse test at screening or check-in.
- •Consumption of alcoholic beverages within 24 hours of check-inor during confinement.
- •Subjects who, in the opinion of the Investigator, are unsuitable for participation in the clinical investigation.
研究组 & 干预措施
Fleet enema
Active Comparator
This group will receive Fleet enema as their treatment
干预措施: Fleet enema (Drug)
TF037
Experimental
This group will receive TF037 as their treatment
干预措施: TF037 (Device)
结局指标
主要结局
Performance of TF037 in distal bowel cleansing compared to Fleet enema using the Harefield Cleansing scale
时间窗: Between 1 to 3 hours following enema administration
次要结局
- Stool output as measured by stool weight(up to 1 hour following enema administration)
- Safety and tolerability as assessed by use of a Visual Analogue scale (VAS)(5 and 30 minutes following enema administration)
- Stool output over time(1 hour following enema administration)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Clinical Trial of a New Rectum Cooling System on Patients of Hypoxic-ischemic Brain DamageHypoxic-Ischemic EncephalopathyNCT02544542Children's Hospital of Chongqing Medical University70
已完成
不适用
Evaluation of a Novel Medical Device to Facilitate Gel Instillation During Change of Long-term Urinary CathetersUrinary CathetersRetention, UrinaryIncontinence, UrinaryAnesthesia, LocalNCT03289117Region Skane32
终止
不适用
Efficacy of Micro-Patterned Foley Catheter to Reduce Catheter-Associated Urinary Tract InfectionUrinary Tract InfectionNCT02198833Baylor College of Medicine2
已完成
不适用
Uro-NIRS Clinical StudyLower Urinary Tract SymptomsOveractive BladderNCT00706407Weill Medical College of Cornell University42
已完成
不适用
Extending Urine Analysis By Direct Mass SpectrometryUrinary Tract Infection (Diagnosis)NCT02966977University Hospital, Basel, Switzerland192